Events Calendar
Next earnings date:
May 09, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Recently experiencing a decrease in value, AEON Biopharma, Inc. (AEON) has now shown a hammer chart pattern, suggesting that the stock has found a level of support. This, along with an increase in earnings estimate revisions, may result in a potential turnaround for the stock in the near future.
Atalaya Capital Management LP (Trades, Portfolio), a New York-based investment firm, recently made a significant acquisition in AEON Biopharma Inc. This article will delve into the details of the transaction, provide an overview of both Atalaya Capital Management LP (Trades, Portfolio) and AEON Biopharma Inc, and analyze the potential impact of this acquisition on the firm's portfolio and the traded company's stock performance.
FAQ
- What is the primary business of AEON Biopharma?
- What is the ticker symbol for AEON Biopharma?
- Does AEON Biopharma pay dividends?
- What sector is AEON Biopharma in?
- What industry is AEON Biopharma in?
- What country is AEON Biopharma based in?
- When did AEON Biopharma go public?
- Is AEON Biopharma in the S&P 500?
- Is AEON Biopharma in the NASDAQ 100?
- Is AEON Biopharma in the Dow Jones?
- When was AEON Biopharma's last earnings report?
- When does AEON Biopharma report earnings?
- Should I buy AEON Biopharma stock now?